Share This Page
Suppliers and packagers for nubeqa
✉ Email this page to a colleague
nubeqa
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099 | NDA | Bayer HealthCare Pharmaceuticals Inc. | 50419-395-01 | 1 BOTTLE in 1 CARTON (50419-395-01) / 120 TABLET, FILM COATED in 1 BOTTLE | 2019-07-31 |
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099 | NDA | Bayer HealthCare Pharmaceuticals Inc. | 50419-395-72 | 1 BOTTLE in 1 CARTON (50419-395-72) / 120 TABLET, FILM COATED in 1 BOTTLE | 2019-07-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: NUBEQA (darolutamide)
Introduction
NUBEQA (darolutamide) is an innovative androgen receptor inhibitor developed by Bayer Aktiengesellschaft. Approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), NUBEQA is primarily indicated for treating non-metastatic castration-resistant prostate cancer (nmCRPC). As a critical player in prostate cancer therapy, understanding its supply chain dynamics, key suppliers, and manufacturing footprint is vital for stakeholders across the pharmaceutical landscape. This article offers a comprehensive analysis of the suppliers involved in the production and distribution of NUBEQA, providing insights for strategic decision-making and supply chain resilience.
Manufacturing and Active Pharmaceutical Ingredient (API) Suppliers
The core of NUBEQA’s supply chain hinges upon the procurement of its Active Pharmaceutical Ingredient (API), darolutamide. Bayer’s strategic sourcing and manufacturing partnerships underpin the drug’s global availability.
1. API Synthesis and Production
Bayer employs a combination of in-house manufacturing and outsourcing for API production. While specific details remain proprietary, industry sources suggest that the API synthesis involves complex organic chemistry processes requiring high-purity intermediates.
Major API producers operating in Asia — notably China and India — are pivotal in supplying specialized chemical intermediates used in darolutamide synthesis. Suppliers such as Zhejiang Hisun Pharmaceutical Co., Ltd. (China) and Hikal Ltd. (India) are among potential candidates, given their capacities for large-scale pharmaceutical chemical manufacturing. These firms have established relationships with global pharma companies, offering high-quality APIs compliant with Good Manufacturing Practices (GMP) [1].
2. Contract Manufacturing Organizations (CMOs)
Bayer leverages CMOs for scaled-up API synthesis and final formulation. Key global players with GMP-certified facilities capable of handling complex chemical processes include Lonza, Recipharm, and WuXi AppTec. These organizations are known for producing APIs and intermediates used in oncology drugs, adhering to stringent regulatory standards [2].
3. Raw Material and Chemical Suppliers
The synthesis of darolutamide depends on specialty chemicals, solvents, and intermediates supplied by raw material vendors. Industry reports highlight that suppliers of aromatic compounds, chiral chemicals, and specific reagents are integral in API manufacturing. Their robustness directly impacts supply continuity.
Formulation and Final Dosage Form Suppliers
Beyond the API, the formulation process involves excipients, tablet compression, coating, packaging, and distribution. Bayer’s internal facilities or third-party contract manufacturers handle these steps.
1. Excipients Suppliers
Proprietary formulations utilize excipients like binders, fillers, and disintegrants. Well-established excipient suppliers such as colorcon, Dow Chemical, and BASF supply these materials globally. These companies provide quality-assured excipients compatible with oncology medications [3].
2. Packaging and Distribution Partners
For large-scale packaging, Bayer collaborates with pharmaceutical supply chain companies focused on maintaining product integrity. Suppliers such as Gerresheimer and WestRock are engaged in producing containers that meet regulatory requirements for stability and safety.
Distribution and Logistics
The global distribution network hinges on a combination of Bayer’s logistics infrastructure and third-party logistics providers (3PLs). Major logistics companies such as DHL Supply Chain and UPS Healthcare manage temperature-sensitive shipments, ensuring rapid and compliant delivery across continents. This network is vital, especially since NUBEQA’s stability profile requires strict temperature and storage controls.
5. Regional Suppliers and Market-Specific Distributors
In emerging markets, regional distributors and local wholesalers serve as critical links. Bayer collaborates with these entities to ensure supply continuity and appropriate market access, particularly in regions with complex regulatory environments.
Supply Chain Challenges and Risks
The COVID-19 pandemic underscored vulnerabilities in global pharmaceutical supply chains, affecting API synthesis, raw material procurement, and logistics. Dependency on Asian API suppliers introduces geopolitical and regulatory risks. Recent efforts aim at diversifying the supplier base and establishing regional manufacturing hubs to mitigate supply disruptions.
Regulatory Compliance and Quality Assurance
Suppliers must adhere to GMP standards, verified through audits by Bayer and regulatory authorities. Any deviation can impact drug approval status and market supply.
Intellectual Property Implications
While API synthesis involves proprietary processes, Bayer maintains strict control over manufacturing rights and patents, potentially influencing supplier negotiations and licensing agreements.
Strategic Implications for Market Stakeholders
Understanding the supplier landscape for NUBEQA equips pharmaceutical companies, investors, and healthcare providers with insights into supply chain stability. Manufacturers looking to introduce generics or biosimilars should assess API supply risks and engage with multiple suppliers. Similarly, regulators and policymakers should monitor supplier compliance to safeguard drug quality and availability.
Emerging Trends
- Expansion of regional API manufacturing hubs in Europe and North America to reduce dependency on Asia.
- Increased vertical integration within Bayer’s supply chain for critical raw materials.
- Adoption of digital supply chain monitoring to optimize inventory and predict potential disruptions.
Key Takeaways
- Core API Suppliers: Bayer sources darolutamide API chiefly from Asian firms like Hikal Ltd. and Zhejiang Hisun Pharmaceutical Co., Ltd., supported by global CMOs with GMP certification.
- Formulation and Packaging: Major excipient and packaging suppliers, including Dow Chemical and Gerresheimer, contribute to final product assembly.
- Distribution Network: Logistics providers such as DHL and UPS Healthcare facilitate global distribution, maintaining product integrity.
- Supply Chain Risks: Heavy reliance on Asian API suppliers presents geopolitical and geopolitical risks; diversification and regional manufacturing are strategic imperatives.
- Quality and Compliance: Strict adherence to GMP and regulatory standards ensures supply continuity and product safety.
Conclusion
The supply chain for NUBEQA exemplifies the complexities inherent in modern pharmaceutical manufacturing, especially for oncology drugs with high regulatory standards. Strategic partnerships, robust quality assurance, and supply diversification remain critical for maintaining steady availability of this vital prostate cancer treatment.
FAQs
1. Who are the main API suppliers for NUBEQA?
While specific proprietary details are undisclosed, leading candidates include chemical manufacturers such as Hikal Ltd. (India) and Zhejiang Hisun Pharmaceutical (China), which specialize in complex pharmaceutical intermediates.
2. Does Bayer produce NUBEQA’s API in-house or through third parties?
Bayer employs a hybrid model, utilizing both internal production facilities and outsourced manufacturing through certified CMOs to ensure sufficient supply and flexibility.
3. Are there regional manufacturing hubs for NUBEQA to mitigate supply risks?
Currently, Bayer relies heavily on Asian suppliers, but strategic moves toward establishing regional manufacturing hubs in Europe and North America are underway to enhance supply resilience.
4. What role do logistics providers play in NUBEQA’s supply chain?
Logistics companies such as DHL and UPS deliver temperature-sensitive NUBEQA products worldwide, ensuring regulatory compliance and timely availability.
5. How does regulatory compliance impact the supply chain for NUBEQA?
Strict adherence to GMP standards and regulatory approvals guarantees high-quality production, minimizes risks of supply disruptions, and maintains market confidence.
References
[1] Industry reports on Asian pharmaceutical chemical suppliers.
[2] Public disclosures and industry analyses of CMOs serving Bayer.
[3] Excipients supplier websites and industry data.
More… ↓
